Asia Pacific Nuclear Medicine Market worth $4.68 billion by 2030
The report "Asia Pacific Nuclear Medicine Market by Type (SPECT [Tc99m, I-123, Ga-67], PET [F-18, Rb-82], Alpha Emitters, Beta Emitters [Y-90], Brachytherapy), Application (Onco, Thyroid, Cardio), Procedure, End User (Imaging Center, Hospital) - Forecast to 2030" is projected to grow from USD 2.13 billion in 2025 and to reach USD 4.68 billion by 2030, at a Compound Annual Growth Rate (CAGR) of 17.1% during the forecast period.
Browse 170 market data Tables and 10 Figures spread through 250 Pages and in-depth TOC on "Asia Pacific Nuclear Medicine Market by Type (SPECT [Tc99m, I-123, Ga-67], PET [F-18, Rb-82], Alpha Emitters, Beta Emitters [Y-90], Brachytherapy), Application (Onco, Thyroid, Cardio), Procedure, End User (Imaging Center, Hospital) - Forecast to 2030"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/asia-pacific-nuclear-medicine-market-258627235.html
The Asia Pacific nuclear medicine market is projected to grow from USD 2.13 billion in 2025 to USD 4.68 billion by 2030, at a CAGR of 17.1% during the forecast period.
The regional market is driven by the growing application of radiopharmaceuticals and radioisotopes due to the increased cancer burden, the growing use of PET and SPECT imaging, and the expanding nuclear medicine infrastructure. The rapidly rising use of theranostics is boosting market growth during the forecast period. Investments in cyclotron facilities and local radiopharmaceutical manufacturing, especially in China and India, drive the market in the region.
“Diagnostic segment accounted for the largest share of the Asia Pacific nuclear medicine market in 2024”
In 2024, the diagnostic nuclear medicine segment accounted for the largest share of the Asia Pacific nuclear medicine market. This is attributed to the routine clinical dependence on diagnostic radiopharmaceuticals as the first line of imaging in high-patient-volume health care systems in the region. Diagnostic nuclear medicine is less complex to perform procedurally, has a shorter turnaround time, and is not limited by reimbursement tools, such as therapeutic nuclear medicine, which are more generally used in hospitals and imaging facilities. Moreover, the high population base, the growing referral base, and the continued growth of PET/ CT and SPECT/CT systems in China, India, and Japan provided increased procedure throughput, allowing the diagnostic segment to have the largest market share in 2024.
“Hospitals segment is the fastest-growing segment, by end user, between 2025 and 2030”
The hospitals segment is expected to register the fastest growth rate during the forecast period. This is attributed to changes in nuclear medicine practice, where it is no longer practised as a single imaging facility, but rather as a pathway of care led by the hospital in Asia Pacific. As nuclear medicine is becoming increasingly interconnected with oncology, cardiology, and surgical units, hospitals are becoming more centralized where isotopes are handled, the patient is prepared, and post-procedural monitoring is provided. Additionally, hospitals can more easily address regulatory needs, radioactive waste management, and isotope logistics. It makes them the preferred choice in scaling radiopharmaceutical applications. The forecast period is witnessing increased growth of the hospital segment, which is being driven by this structural change in the service delivery.
“China is likely to account for a major share of the Asia Pacific nuclear medicine market in 2030”
China is expected to capture the most significant share of the Asia Pacific nuclear medicine market in 2030. This is attributed to the size of the patient base, government efforts to grow nuclear medicine, and the increasing domestic production of radiopharmaceuticals and radioisotopes. The country has massively invested in the facilities of nuclear medicine, research reactors, and cyclotron networks. This has allowed it to gain greater access to diagnostic and therapeutic radioisotopes. Additionally, state-supported institutions are increasing the use of advanced nuclear medicine services in state hospitals, and positive policy measures are being implemented to enhance cancer diagnostics and treatment. These factors have established the country as a key contributor to the Asia Pacific nuclear medicine market growth.
Key Players
Key players operating in the Asia Pacific nuclear medicine market include GE HealthCare (US), Cardinal Health (US), Curium (France), Bayer AG (Germany), Lantheus Holdings, Inc. (US), Novartis AG (Switzerland), Jubilant Pharmova Limited (India), Bracco Imaging S.P.A (Italy), Pharmalogic Holdings Corp. (US), Sun Pharmaceutical Industries, Inc. (India), Nordion Inc. (Canada), Siemens Healthineers AG (Germany), NorthStar Medical Radiosiotopes, LLC (US), Eckert & Ziegler (Germany), Isotope JSC (Russia), Global Medical Solutions (US), Telix Pharmaceuticals Limited (Australia), PDRadiopharma Inc. (Japan), ITM Isotope Technologies Munich SE (Germany), BWX Technologies Inc. (US), SHINE Technologies, LLC (US), Isotopia (Israel), China Isotope & Radiation Corporation (China), IRE Elit (Turkey), and Cyclopharm (Australia).
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Asia Pacific Nuclear Medicine Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
